MétaCan
Menu
← Back to cohort

Abstract 15007: Time to SGLT2i Initiation in Patients With Heart Failure

2023· article· en· W4389958017 on OpenAlexaffabout
Jungyeon Moon, Jacob A. Udell, Alice Chong, Jiming Fang, Peter C. Austin, Dennis T. Ko, Thérèse A. Stukel, Clare Atzema, Gillian L. Booth, Karen Tu, David Naimark, Cynthia A. Jackevicius

Bibliographic record

VenueCirculation · 2023
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsSunnybrook Health Science CentreInstitute for Clinical Evaluative SciencesUniversity of Toronto
Fundersnot available
KeywordsMedicineMedical prescriptionDiabetes mellitusInternal medicineHeart failureCohortCohort studyEmergency medicineEndocrinology

Abstract

fetched live from OpenAlex

Introduction: SGLT2i, initially introduced as antidiabetic agents, have shown cardiovascular benefits for heart failure (HF) patients, irrespective of their diabetes status. Given the growing evidence from post-hoc analyses of landmark trials advocating for early initiation, this study aims to investigate the temporal trends in the timing of SGLT2i initiation after HF hospitalization. Methods: A cross-sectional study was conducted using administrative health data from Ontario, Canada. Our cohort included patients aged ≥65 years who filled an SGLT2i prescription after their HF hospitalization in Ontario, Canada between 4/2016-3/2021. We computed the median number of days to the first SGLT2i prescription after the HF discharge date, exclusively for patients who started SGLT2i. Patients were further stratified based on their diabetes status. Results: We identified 64,183 HF patients, of which 5,257 filled an SGLT2i prescription after discharge (mean age was 82.49; 46.9% men; 49.6% had diabetes). The number of patients starting an SGLT2i increased from 889 (16.9%) in 2016/17 to 1,206 (22.9%) by 2020/21. The median time from discharge following the index HF admission to first dispensation of an SGLT2i prescription decreased 7-fold over this period, from 1,082 days to 156 days (Figure 1). In 2016/17, patients with diabetes started an SGLT2i at a median of 930 days, and patients without diabetes at 1,640 days. However, by 2020/21, the median initiation times were closer at 143 and 189 days, respectively. Conclusions: Our findings demonstrate a substantial reduction in the time to SGLT2i initiation for patients after HF admission, suggesting increased clinician recognition of their cardiovascular benefits. However, initiation remains delayed, especially for patients without diabetes. To optimize patient outcomes, it is crucial to encourage early initiation of SGLT2i therapy in hospitalized HF patients and address potential barriers to SGLT2i initiation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.210
Threshold uncertainty score0.418

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.231
Teacher spread0.220 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueCirculation→Same topicDiabetes Treatment and Management→French-language works237,207→